{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:52:00Z","timestamp":1778593920154,"version":"3.51.4"},"reference-count":43,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T00:00:00Z","timestamp":1531785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"pharmaceutical company CelonPharma S.A.","award":["STRATEGMED2\/ 266776\/17\/NCBR\/2015"],"award-info":[{"award-number":["STRATEGMED2\/ 266776\/17\/NCBR\/2015"]}]},{"name":"Polish National Center of Research and Development","award":["STRATEGMED2\/ 266776\/17\/NCBR\/2015"],"award-info":[{"award-number":["STRATEGMED2\/ 266776\/17\/NCBR\/2015"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>High-grade serous ovarian carcinoma (HGSOC) is the most frequent histological type of ovarian cancer and the one with worst prognosis. Unfortunately, the majority of established ovarian cancer cell lines which are used in the research have unclear histological origin and probably do not represent HGSOC. Thus, new and reliable models of HGSOC are needed. Ascitic fluid from a patient with recurrent HGSOC was used to establish a stable cancer cell line. Cells were characterized by cytogenetic karyotyping and short tandem repeat (STR) profiling. New generation sequencing was applied to test for hot-spot mutations in 50 cancer-associated genes and fluorescence in situ hybridization (FISH) analysis was used to check for TP53 status. Cells were analyzed for expression of several marker genes\/proteins by reverse-transcription polymerase chain reaction (RT-PCR), fluorescence-activated cell sorting (FACS), and immunocytochemistry (ICC). Functional tests were performed to compare OVPA8 cells with five commercially available and frequently used ovarian cancer cell lines: SKOV3, A2780, OVCAR3, ES2, and OAW42. Our newly-established OVPA8 cell line shows morphologic and genetic features consistent with HGSOC, such as epithelial morphology, multiple chromosomal aberrations, TP53 mutation, BRCA1 mutation, and loss of one copy of BRCA2. The OVPA8 line has a stable STR profile. Cells are positive for EpCAM, CK19, and CD44; they have relatively low plating efficiency\/ability to form spheroids, a low migration rate, and intermediate invasiveness in matrigel, as compared to other ovarian cancer lines. OVPA8 is sensitive to paclitaxel and resistant to cisplatin. We also tested two FGFR inhibitors; OVPA8 cells were resistant to AZD4547 (AstraZeneca, London, UK), but sensitive to the new inhibitor CPL304-110-01 (Celon Pharma, \u0141omianki\/Kie\u0142pin, Poland). We have established and characterized a novel cell line, OVPA8, which can be a valuable preclinical model for studies on high-grade serous ovarian cancer.<\/jats:p>","DOI":"10.3390\/ijms19072080","type":"journal-article","created":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T08:45:42Z","timestamp":1531903542000},"page":"2080","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8"],"prefix":"10.3390","volume":"19","author":[{"given":"Patrycja","family":"Tudrej","sequence":"first","affiliation":[{"name":"Center for Translational Research and Molecular Biology of Cancer, Maria Sk\u0142odowskaj-Curie Institute\u2014Oncology Center, Gliwice Branch, ul. Wybrze\u017ce Armii Krajowej 15, 44-101 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Olbryt","sequence":"additional","affiliation":[{"name":"Center for Translational Research and Molecular Biology of Cancer, Maria Sk\u0142odowskaj-Curie Institute\u2014Oncology Center, Gliwice Branch, ul. Wybrze\u017ce Armii Krajowej 15, 44-101 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Zembala-No\u017cy\u0144ska","sequence":"additional","affiliation":[{"name":"Thumor Pathology Department, Maria Sk\u0142odowskaj-Curie Institute\u2014Oncology Center, Gliwice Branch, ul. Wybrze\u017ce Armii Krajowej 15, 44-101 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna A.","family":"Kujawa","sequence":"additional","affiliation":[{"name":"Center for Translational Research and Molecular Biology of Cancer, Maria Sk\u0142odowskaj-Curie Institute\u2014Oncology Center, Gliwice Branch, ul. Wybrze\u017ce Armii Krajowej 15, 44-101 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander J.","family":"Cortez","sequence":"additional","affiliation":[{"name":"Center for Translational Research and Molecular Biology of Cancer, Maria Sk\u0142odowskaj-Curie Institute\u2014Oncology Center, Gliwice Branch, ul. Wybrze\u017ce Armii Krajowej 15, 44-101 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Fiszer-Kierzkowska","sequence":"additional","affiliation":[{"name":"Molecular Diagnostics Laboratory, Maria Sk\u0142odowskaj-Curie Institute\u2014Oncology Center, Gliwice Branch, ul. Wybrze\u017ce Armii Krajowej 15, 44-101 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Pig\u0142owski","sequence":"additional","affiliation":[{"name":"Molecular Diagnostics Laboratory, Maria Sk\u0142odowskaj-Curie Institute\u2014Oncology Center, Gliwice Branch, ul. Wybrze\u017ce Armii Krajowej 15, 44-101 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Nikiel","sequence":"additional","affiliation":[{"name":"Thumor Pathology Department, Maria Sk\u0142odowskaj-Curie Institute\u2014Oncology Center, Gliwice Branch, ul. Wybrze\u017ce Armii Krajowej 15, 44-101 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"G\u0142owala-Kosi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation and Hematology-Oncology, Maria Sk\u0142odowskaj-Curie Institute\u2014Oncology Center, Gliwice Branch, ul. Wybrze\u017ce Armii Krajowej 15, 44-101 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Bartkowska-Chrobok","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Andrzej Miel\u0119cki Independent Public Hospital, ul. D\u0105browskiego 25, 40-032 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6722-8881","authenticated-orcid":false,"given":"Andrzej","family":"Smagur","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation and Hematology-Oncology, Maria Sk\u0142odowskaj-Curie Institute\u2014Oncology Center, Gliwice Branch, ul. Wybrze\u017ce Armii Krajowej 15, 44-101 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5953-7131","authenticated-orcid":false,"given":"Wojciech","family":"Fidyk","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation and Hematology-Oncology, Maria Sk\u0142odowskaj-Curie Institute\u2014Oncology Center, Gliwice Branch, ul. Wybrze\u017ce Armii Krajowej 15, 44-101 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9786-3993","authenticated-orcid":false,"given":"Katarzyna M.","family":"Lisowska","sequence":"additional","affiliation":[{"name":"Center for Translational Research and Molecular Biology of Cancer, Maria Sk\u0142odowskaj-Curie Institute\u2014Oncology Center, Gliwice Branch, ul. Wybrze\u017ce Armii Krajowej 15, 44-101 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,7,17]]},"reference":[{"key":"ref_1","unstructured":"(2018, June 01). National Cancer Institute: Cell Lines in the In Vitro Screen, Available online: https:\/\/dtp.cancer.gov\/discovery_development\/nci-60\/cell_list.htm."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1136\/mp.55.5.294","article-title":"Further evidence to support the melanocytic origin of MDA-MB-435","volume":"55","author":"Ellison","year":"2002","journal-title":"J. Clin. Pathol. Mol. Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10549-006-9392-8","article-title":"MDA-MB-435 cells are derived from M14 melanoma cells\u2014A loss for breast cancer, but a boon for melanoma research","volume":"104","author":"Rae","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1158\/0008-5472.CAN-09-1528","article-title":"MDA-MB-435 and M14 Cell Lines: Identical but not M14 Melanoma?","volume":"69","author":"Chambers","year":"2009","journal-title":"Cancer Res."},{"key":"ref_5","first-page":"8634","article-title":"Karyotypic complexity of the NCI-60 drug-screening panel","volume":"63","author":"Roschke","year":"2003","journal-title":"Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/217750a0","article-title":"Apparent Hela Cell Contamination of Human Heteroploid Cell Lines","volume":"217","author":"Gartler","year":"1968","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/jnci\/58.2.209","article-title":"Absence of Hela-Cell Contamination in 169 Cell Lines Derived from Human Tumors","volume":"58","author":"Fogh","year":"1977","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40661-015-0008-z","article-title":"Adenocarcinoma of Mullerian origin: Review of pathogenesis, molecular biology, and emerging treatment paradigms","volume":"2","author":"Cobb","year":"2015","journal-title":"Gynecol. Oncol. Res. Pract."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.5604\/17322693.1184451","article-title":"Ovarian cancer\u2014From biology to clinic","volume":"69","author":"Kujawa","year":"2015","journal-title":"Postep. Hig. Med. Dosw."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Beaufort, C.M., Helmijr, J.C.A., Piskorz, A.M., Hoogstraat, M., Ruigrok-Ritstier, K., Besselink, N., Murtaza, M., van IJcken, W.F.J., Heine, A.A.J., and Smid, M. (2014). Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0103988"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms3126","article-title":"Evaluating cell lines as tumour models by comparison of genomic profiles","volume":"4","author":"Domcke","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Bartlett, J.M.S. (2000). Establishment of ovarian cancer cell lines. Ovarian Cancer. Methods and Protocols, Humana Press.","DOI":"10.1385\/1592590713"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-018-0514-2","article-title":"Different TP53 mutants in p53 overexpressed epithelial ovarian carcinoma can be associated both with altered and unaltered glycolytic and apoptotic profiles","volume":"18","author":"Antoun","year":"2018","journal-title":"Cancer Cell Int."},{"key":"ref_14","unstructured":"(2018, June 01). NCBI ClinVar Database: NM_000546.5(TP53):c.733G>A (p.Gly245Ser), Available online: https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/variation\/12365\/."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Anglesio, M.S., Wiegand, K.C., Melnyk, N., Chow, C., Salamanca, C., Prentice, L.M., Senz, J., Yang, W.N., Spillman, M.A., and Cochrane, D.R. (2013). Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research. PLoS ONE, 8.","DOI":"10.1371\/annotation\/856f0890-9d85-4719-8e54-c27530ac94f4"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1158\/1535-7163.MCT-06-0433","article-title":"Mutation analysis of 24 known cancer genes in the NCI-60 cell line set","volume":"5","author":"Ikediobi","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/humu.10298","article-title":"Novel TP53 gene mutations in tumors of Russian patients with breast cancer detected using a new solid phase chemical cleavage of mismatch method and identified by sequencing","volume":"23","author":"Lambrinakos","year":"2004","journal-title":"Hum. Mutat."},{"key":"ref_18","first-page":"17","article-title":"The value of PAX8 and WT1 molecules in ovarian cancer diagnosis","volume":"54","author":"Liliac","year":"2013","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1309\/AJCPU0FION3RKKFO","article-title":"Value of PAX8 and WT1 Immunostaining in Confirming the Ovarian Origin of Metastatic Carcinoma in Serous Effusion Specimens","volume":"137","author":"Zhao","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","article-title":"The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory","volume":"34","author":"Kurman","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1097\/PAS.0b013e31816d71ad","article-title":"Expression of Pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas","volume":"32","author":"Nonaka","year":"2008","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms8419","article-title":"Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours","volume":"6","author":"Ince","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1158\/1078-0432.CCR-15-0534","article-title":"MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer","volume":"22","author":"Hew","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12943-017-0638-3","article-title":"Ovarian cancer stem cells: Still an elusive entity?","volume":"16","author":"Lupia","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_25","first-page":"48","article-title":"Surface markers of cancer stem-like cells of ovarian cancer and their clinical relevance","volume":"22","author":"Klemba","year":"2018","journal-title":"Contemp. Oncol. (Pozn.)"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1158\/1078-0432.CCR-11-2188","article-title":"Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer","volume":"18","author":"Steg","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1002\/jcb.23199","article-title":"Cisplatin Treatment of Primary and Metastatic Epithelial Ovarian Carcinomas Generates Residual Cells With Mesenchymal Stem Cell-Like Profile","volume":"112","author":"Latifi","year":"2011","journal-title":"J. Cell. Biochem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/stem.582","article-title":"Side Population is Not Necessary or Sufficient for a Cancer Stem Cell Phenotype in Glioblastoma Multiforme","volume":"29","author":"Broadley","year":"2011","journal-title":"Stem Cells"},{"key":"ref_29","unstructured":"Zdzalik, D.G.P., Lipner, J., Bujak, A., Dymek, B., Gunerka, P., Stanczak, A., Lamparska-Przybysz, M., Wieczorek, M., and Dzwonek, K. (October, January 27). Design and development of active and selective FGFR kinase inhibitor CPL-043 as potential anticancer targeted therapy. Proceedings of the European Cancer Congress, Amstedram, The Netherlands."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00432-016-2147-y","article-title":"Unsupervised analysis reveals two molecular subgroups of serous ovarian cancer with distinct gene expression profiles and survival","volume":"142","author":"Lisowska","year":"2016","journal-title":"J. Cancer Res. Clin."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Fogh, J. (1975). New Human Tumor Cell Lines. Human Tumor Cells In Vitro, Springer.","DOI":"10.1007\/978-1-4757-1647-4"},{"key":"ref_32","first-page":"285","article-title":"Experimental-Model Systems of Ovarian-Cancer\u2014Applications to the Design and Evaluation of New Treatment Approaches","volume":"11","author":"Hamilton","year":"1984","journal-title":"Semin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.ymthe.2004.08.013","article-title":"Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer","volume":"10","author":"Shaw","year":"2004","journal-title":"Mol. Ther."},{"key":"ref_34","first-page":"5181","article-title":"Multifactorial Mechanisms Associated with Broad Cross-Resistance of Ovarian-Carcinoma Cells Selected by Cyanomorpholino Doxorubicin","volume":"51","author":"Lau","year":"1991","journal-title":"Cancer Res."},{"key":"ref_35","first-page":"513","article-title":"Characterization of a Cell-Line Derived from the Ascites of a Patient with Papillary Serous Cystadenocarcinoma of the Ovary","volume":"72","author":"Wilson","year":"1984","journal-title":"J. Natl. Cancer Inst"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ygyno.2015.08.017","article-title":"Beyond genomics: Critical evaluation of cell line utility for ovarian cancer research","volume":"139","author":"Elias","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s10147-012-0459-8","article-title":"Clinical trials and future potential of targeted therapy for ovarian cancer","volume":"17","author":"Itamochi","year":"2012","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","article-title":"Advances in ovarian cancer therapy","volume":"81","author":"Cortez","year":"2018","journal-title":"Cancer Chemoth. Pharm."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/onc.2016.337","article-title":"Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer","volume":"36","author":"Witt","year":"2017","journal-title":"Oncogene"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2010\/904767","article-title":"Detection of EBV, HBV, HCV, HIV-1, HTLV-I and-II, and SMRV in Human and Other Primate Cell Lines","volume":"2010","author":"Uphoff","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_41","first-page":"1","article-title":"Chromosome Preparation from Cultured Cells","volume":"83","author":"Howe","year":"2014","journal-title":"JoVE J. Vis. Exp."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s13353-011-0040-6","article-title":"Prevalence of the most frequent BRCA1 mutations in Polish population","volume":"52","author":"Brozek","year":"2011","journal-title":"J. Appl. Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.advms.2016.12.002","article-title":"A novel germline TP53 mutation p.Pro190Arg detected in a patient with lung and bilateral breast cancers","volume":"62","author":"Krzesniak","year":"2017","journal-title":"Adv. Med. Sci. Pol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/7\/2080\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:12:39Z","timestamp":1760195559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/7\/2080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,17]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7]]}},"alternative-id":["ijms19072080"],"URL":"https:\/\/doi.org\/10.3390\/ijms19072080","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,17]]}}}